Seeking Alpha (Free subscription) | 07/22/2008
Forest Laboratories Inc. (FRX) F4Q09 (Qtr End 6/30/08) Earnings Call Complete Story »
The Earth Times Online Newspaper (Free subscription) | 07/22/2008
NEW YORK (Reuters) - Forest Laboratories Inc reported a 9 percent decline in quarterly profit on Tuesday on higher sales and administrative costs, but results were better than expected and the company forecast fiscal-year earnings ahead of analyst projections.
Reuters (Free subscription) | 07/22/2008
NEW YORK (Reuters) - Forest Laboratories Inc reported a 9 percent decline in quarterly profit on Tuesday on higher sales and administrative costs, but results were better than expected and the company forecast fiscal-year earnings ahead of analyst projections.
Market Watch (Free subscription) | 07/22/2008
NEW YORK (MarketWatch) -- Forest Laboratories Inc. said Tuesday that it earned $242.9 million, or 79 cents a share, in its first quarter, down from $268.2 million, or 83 cents a share, in the year-earlier period. The latest results included a charge of 8 cents a share, related to a terminated co-promotion agreement with Daiichi Sankyo. The New York pharmaceutical company said revenue for the quarter...
Seeking Alpha (Free subscription) | 07/21/2008
Forest Laboratories (FRX) is expected to report Q1 earnings before market open Tuesday, with a conference call scheduled for 10:00 am ET. Guidance Analysts are looking for a profit of 80c on revenue of $978.86M. The consensus is 72c to 87c for EPS, and revenue of $931.58M to $1.01B, according to First Call. The company reported Q4 EPS 90c vs. consensus of 76c and Q4 revenue $990.85M vs. consensus...
PR News Wire (Free subscription) | 06/30/2008
NEW YORK, June 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: ), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2009 First Quarter financial results before the U.S. stock market opens on Tuesday, July 22, 2008. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer...
Life Science World (Free subscription) | 06/25/2008
[JOB] Forest Laboratories, Commack, NY, USA
Life Science World (Free subscription) | 06/25/2008
[JOB] Forest Laboratories, New York, NY, USA
Life Science World (Free subscription) | 06/25/2008
[JOB] Forest Laboratories, St-Louis, MO, USA
Life Science World (Free subscription) | 06/25/2008
[JOB] Forest Laboratories, New York, NY, USA
Medical News Today (Free subscription) | 06/20/2008
Forest Laboratories, Inc. (NYSE: FRX) announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as MRSA and gram negative bacteria, for the treatment of complicated skin and skin structure infections (cSSSI).
Medical News Today (Free subscription) | 06/20/2008
Forest Laboratories, Inc. (NYSE: FRX) announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as MRSA and gram negative bacteria, for the treatment of complicated skin and skin structure infections (cSSSI).
Life Science World (Free subscription) | 06/19/2008
[NEWS] Company’s Next-Generation Cephalosporin Effective Against Difficult-to-Treat Skin Infections, Including Those with methicillin-resistant Staphylococcus aureus (MRSA) NEW YORK, June 19 /PRNewswire-FirstCall/ — Forest Laboratories, Inc. (NYSE: FRX) today announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity...
Medical News Today (Free subscription) | 05/24/2008
Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) today announced the presentation of data from a Phase 2b randomized, double-blind, placebo-controlled study assessing the safety and efficacy of linaclotide in patients with chronic constipation (CC). Analysis of these data indicate that linaclotide met its primary endpoint.
Red Orbit (Free subscription) | 05/21/2008
Almirall and Forest Laboratories have reported encouraging results from four clinical trials assessing the efficacy and safety of aclidinium bromide, an investigational treatment for chronic obstructive pulmonary disease.
The last article published by a user on Forest Laboratories :
sunilnair | 12/25/2007
Forest Laboratories Inc.: PharmaVitae Profile Introduction This analysis examines the historical and forecast performance for Forest in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually...
